IBM (NYSE: IBM) Watson Health™ highlighted its recent clients and collaborations for its IBM Watson Health Imaging artificial intelligence (AI) platform, a leading provider of innovative artificial intelligence, enterprise imaging and interoperability solutions available through multiple products and services trusted by medical professionals worldwide.
IBM Watson Health will be showcasing its suite of solutions across AI and Machine Learning, Enterprise Imaging, Vendor Neutral Archive, Image Viewing and Sharing, and PACS at the RSNA 105th RSNA Scientific Assembly and Annual Meeting in Chicago, IL between December 1 – 6, 2019. The IBM Watson Health booths are located at the North Hall Level 1 – booth 11332B and North Hall Level 3 — booth 6100.
“We are delighted to announce these collaborations at RSNA highlighting our advancements in medical imaging globally,” said Anne Le Grand, General Manager, Imaging, Life Sciences and Oncology, IBM Watson Health. “From helping clinicians to identify potential missed findings to seeing a summary view of patient records quickly, our innovative technologies are at the forefront of Watson Health’s mission to help enable clinicians to more effectively respond to the world’s most pressing health challenges.”
Hardin Memorial Health First Provider to Use Patient Synopsis
In June 2019, Hardin Memorial Health (HMH) announced it would be the first provider to use IBM Watson Imaging Patient Synopsis, which provides a summary view of patients through analytics and extracts insights from patient records to uncover underlying issues.
“Being the first in the world to ‘go live’ with IBM Watson Imaging Patient Synopsis was an enormous milestone for the HMH team. This tool is already helping to empower HMH to assist care givers in their treatment of patients through the use of this revolutionary platform,” said Dennis Johnson, HMH president and CEO. “We look forward to our ongoing collaboration with IBM Watson Health as we continue to care for more than 400,000 Central Kentuckians at our facilities.”
IBM Watson Health Imaging Clinical Review 3.0 Launches in UK
On October 30 2019, Clinical Review 3.0 launched in the UK. The solution is designed to analyze medical imaging studies and their associated reports to identify potential missed findings, helping to facilitate more comprehensive reports, which can potentially lead to higher quality of care for the patient.
IBM Watson Health Imaging has recently engaged with Fortrus Ltd, to grow upon the reseller’s strong relationship with the UK public sector, which includes a single supplier outcome-based Managed Services framework.
Guerbet Signs Exclusive Development Agreement for AI in Prostate Cancer
Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional imaging, also recently signed an exclusive joint development agreement to develop an artificial intelligence software solution to support prostate cancer diagnostics and monitoring, utilizing MR imaging. This deal extends their earlier collaboration regarding liver cancer signed in January, 2018.
IBM Imaging AI Marketplace Launched
The IBM Imaging AI Marketplace is a single-source solution designed to help simplify the complex process of locating, purchasing, deploying and managing the vast array of AI imaging applications. The Imaging AI Marketplace is carefully curated and contains only U.S. Food and Drug Administration (FDA)-cleared solutions alongside Watson Health developed AI solutions. It provides a single location for procurement through deployment, simplifying complex and resource-draining processes, and can be easily accessed via our iConnect™️Enterprise Archive.
